# João Pedro Ferreira

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joao-pedro-ferreira/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,063 |
| Field | Heart Failure Treatment and Management |
| h-index | 65 |
| i10-index | 288 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5100602883 |
| ORCID iD | 0000-0002-2304-6138 |
| Works | 584 |

## Researcher papers

Showing 12 of 14.

- [Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://scholariq.org/papers/empagliflozin-in-heart-failure-with-a-preserved-ejection-fraction/)
- [SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials](https://scholariq.org/papers/sglt2-inhibitors-in-patients-with-heart-failure-with-reduced-ejection-fraction-a/)
- [The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial](https://scholariq.org/papers/the-sglt2-inhibitor-empagliflozin-in-patients-hospitalized-for-acute-heart/)
- [Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials](https://scholariq.org/papers/estimating-lifetime-benefits-of-comprehensive-disease-modifying-pharmacological/)
- [Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction](https://scholariq.org/papers/effect-of-empagliflozin-on-the-clinical-stability-of-patients-with-heart-failure/)
- [Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status](https://scholariq.org/papers/effect-of-empagliflozin-on-cardiovascular-and-renal-outcomes-in-patients-with/)
- [Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial](https://scholariq.org/papers/effect-of-empagliflozin-on-worsening-heart-failure-events-in-patients-with-heart/)
- [Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function](https://scholariq.org/papers/cardiac-and-kidney-benefits-of-empagliflozin-in-heart-failure-across-the/)
- [Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction](https://scholariq.org/papers/effect-of-empagliflozin-in-patients-with-heart-failure-across-the-spectrum-of/)
- [Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial](https://scholariq.org/papers/impact-of-empagliflozin-on-decongestion-in-acute-heart-failure-the-empulse-trial/)
- [The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial](https://scholariq.org/papers/the-effect-of-spironolactone-on-cardiovascular-function-and-markers-of-fibrosis/)
- [Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis](https://scholariq.org/papers/spironolactone-in-patients-on-chronic-haemodialysis-at-high-risk-of-adverse/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.